سيماغلوتيد يظهر نتائج قوية في فقدان الوزن لدى البالغين فوق سن 65

12 مايو، 2026

من إعداد الذكاء الاصطناعي

يشير تحليل جديد للتجارب السريرية إلى أن سيماغلوتيد، المكون النشط في عقاري أوزيمبيك (Ozempic) وويغوفي (Wegovy)، يساعد كبار السن الذين يعانون من السمنة على فقدان قدر كبير من الوزن وتحسين مؤشرات صحة القلب. وتستند هذه النتائج إلى بيانات مشاركين تبلغ أعمارهم 65 عاماً فما فوق تلقوا الدواء مرة واحدة أسبوعياً إلى جانب اتباع تغييرات في نمط الحياة.

قام باحثون بقيادة البروفيسور لوكا بوسيتو من جامعة بادوفا بفحص نتائج التجارب STEP 1 و3 و4 و5 و8 و9. وركز التحليل على 358 بالغاً تبلغ أعمارهم 65 عاماً أو أكثر ممن يعانون من السمنة ولكن دون إصابة بمرض السكري. ومن بين هؤلاء، تناول 248 شخصاً جرعة 2.4 ملغ من السيماغلوتيد بينما تلقى 110 أشخاص دواءً وهمياً على مدى 68 أسبوعاً.

Study presented at ENDO 2026 links semaglutide to fewer fractures in people with type 2 diabetes

16 يونيو، 2026 من إعداد الذكاء الاصطناعي صورة مولدة بواسطة الذكاء الاصطناعي تم التحقق من الحقائق

Semaglutide was associated with a lower rate of bone fractures and greater reductions in body mass index among adults with type 2 diabetes, according to a retrospective analysis presented at the Endocrine Society’s ENDO 2026 meeting in Chicago.

Study links Ozempic to lower depression and anxiety risks

A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

21 مايو، 2026 من إعداد الذكاء الاصطناعي تم التحقق من الحقائق

A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.

Health

Updated POWER framework urges multidisciplinary obesity care beyond GLP-1 drugs

Health

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Health

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

Gut reset procedure limits weight regain after stopping Ozempic

A minimally invasive procedure called duodenal mucosal resurfacing may help patients maintain weight loss after discontinuing drugs like Ozempic and tirzepatide. Early results from the REMAIN-1 clinical trial show treated participants regained far less weight than those in a control group after six months off medication. The findings are set for presentation at Digestive Disease Week 2026.

Novo Nordisk heads to South African court over semaglutide copies

10 يونيو، 2026 من إعداد الذكاء الاصطناعي

Danish drugmaker Novo Nordisk is taking a local compounding pharmacy to court in Pretoria to stop the sale of unregistered semaglutide products. The High Court application targets iDexis over patient safety concerns.

France reimburses Mounjaro and Wegovy for severe obesity

Starting this Monday, social security covers Mounjaro and Wegovy for patients with severe obesity or diabetes. It is a first in Europe.

17 يونيو 2026 22:43

Rutgers study finds GLP-1 drug use is tied to a weaker link between impulsivity and self-reported violence

16 يونيو 2026 07:37

Claims-data study finds many people with type 2 diabetes restart GLP-1 drugs after stopping

15 يونيو 2026 07:24

Oral GLP-1 pill shows strong results in diabetes trial

14 يونيو 2026 20:36

Study: Physical activity fell after some patients with obesity started GLP-1 drugs

06 يونيو 2026 09:59

Study links GLP-1 drugs to lower breast cancer risk

23 مايو 2026 05:26

Analysis of FDA reports finds stronger safety signal for rare optic nerve injury with Wegovy than with Ozempic

08 مايو 2026 00:46

Trojan horse obesity drug boosts weight loss in mice

05 مايو 2026 14:05

Study finds people who use Ozempic-like drugs for weight loss face added stigma

25 أبريل 2026 05:27

Young Indians risk health with Ozempic, Mounjaro for pre-wedding weight loss

09 أبريل 2026 23:54

سيماغلوتيد يظهر نتائج قوية في فقدان الوزن لدى البالغين فوق سن 65

مقالات ذات صلة

Study presented at ENDO 2026 links semaglutide to fewer fractures in people with type 2 diabetes

Study links Ozempic to lower depression and anxiety risks

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

Updated POWER framework urges multidisciplinary obesity care beyond GLP-1 drugs

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Japanese study links GLP-1 response to ‘external eating’ habits in people with type 2 diabetes

Gut reset procedure limits weight regain after stopping Ozempic

Novo Nordisk heads to South African court over semaglutide copies

France reimburses Mounjaro and Wegovy for severe obesity

Rutgers study finds GLP-1 drug use is tied to a weaker link between impulsivity and self-reported violence

Claims-data study finds many people with type 2 diabetes restart GLP-1 drugs after stopping

Oral GLP-1 pill shows strong results in diabetes trial

Study: Physical activity fell after some patients with obesity started GLP-1 drugs

Study links GLP-1 drugs to lower breast cancer risk

Analysis of FDA reports finds stronger safety signal for rare optic nerve injury with Wegovy than with Ozempic

Trojan horse obesity drug boosts weight loss in mice

Study finds people who use Ozempic-like drugs for weight loss face added stigma

Young Indians risk health with Ozempic, Mounjaro for pre-wedding weight loss

Vanderbilt study finds muscle loss with weight loss drugs and surgery

يستخدم هذا الموقع ملفات تعريف الارتباط